A multicenter, open-label study using the MIDAS questionnaire to assess the effect of using the HCPC guidelines for migraine management in primary care, including the use of Zomig-ZMT (zolmitriptan) orally disintegrating tablets 5.0mg and Zomig nasal spray 5.0mg as indicated

Trial Profile

A multicenter, open-label study using the MIDAS questionnaire to assess the effect of using the HCPC guidelines for migraine management in primary care, including the use of Zomig-ZMT (zolmitriptan) orally disintegrating tablets 5.0mg and Zomig nasal spray 5.0mg as indicated

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2009

At a glance

  • Drugs Zolmitriptan; Zolmitriptan
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top